Ozempic (semaglutide) shortage collection
There is a worldwide shortage of this diabetes medicine. TGA alerts relate to the shortage in Australia.
Increased global demand for semaglutide products is impacting availability of Ozempic (semaglutide) in Australia. Alerts on the shortage of Trulicity (dulaglutide) and Mounjaro (tirzepatide) are also accessible from this collection.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Type
Topics
- Shortages (12)
- Prescription medicines (5)
- Alert/Advisory (4)
- Advertising (3)
- Medicines safety (3)
- Regulatory compliance (3)
- Therapeutic goods regulation (3)
- Weight loss products (3)
- Import and export (2)
- Safety (2)
- Australian Register of Therapeutic Goods (ARTG) (1)
- Legislation (1)
- Manufacturing (1)
Read current information and updates at:
The pharmaceutical company that supplies Ozempic, Novo Nordisk, has recently advised the TGA and the Ozempic Medicine Shortage Action Group that supply throughout 2025 will be limited.
Visit the Medicine shortage reports database to search for all medicines in shortage and find information about management actions.
Results for
"[search-keyword]"
Collection content
15 result(s) found, displaying 1 to 10
-
Medicine shortage alertsThe supply of Ozempic (semaglutide) will continue to be limited until 31 December 2025
-
Safety alertsConsumers and health professionals should be aware that counterfeit Ozempic-labelled pens have been imported into Australia. These pens may pose a serious health risk and should not be used. There are clear inconsistencies from the original product to look out for.
-
Medicine shortage alertsThe new KwikPen presentation of Mounjaro is now available but supply of all strengths of Mounjaro vials remains limited.
-
Medicine shortage alertsPharmaceutical company Novo Nordisk has advised us that a new brand of semaglutide approved for chronic weight management, Wegovy, will be available in Australia from early August 2024.
-
BlogSome online health clinics are advertising and selling compounded medicines. However, it is important to know that compounded products are not identical to TGA approved products.
-
Safety alertsWe are aware of an emerging trend for telehealth providers to offer compounded semaglutide-like products. Compounded semaglutide-like products are ‘unapproved’ therapeutic goods and have not been evaluated by us for safety, quality and efficacy.
-
Medicine shortage alertsThe availability of all strengths of Mounjaro (tirzepatide) will be limited until 31 August 2024, due to unexpected high demand. Patients and healthcare professionals should check the Medicine Shortage Reports Database for the latest supply information.
-
Medicine shortage alertsRead advice about not prescribing Ozempic to new patients unless there are no suitable alternatives or there is a compelling clinical reason.
-
Medicine shortage alertsThe supply of Ozempic (semaglutide) in Australia is improving however the shortage continues. Stay updated about how the shortage impacts you.
-
Safety alertsThe TGA has detected fake semaglutide, also known as Ozempic, being illegally imported into Australia.